Search Results

Phanes Therapeutics, Inc. today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company.

Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Astellas Pharma Inc. and Kelonia Therapeutics announced that Xyphos Biosciences, Inc., and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.

Xenetic Biosciences, Inc. today announced the appointment of James Parslow, the Company’s Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024.

Avidity Biosciences, Inc. announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share.

Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).

Pressure BioSciences, Inc. announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that it intends to offer and sell, subject to market and other conditions, $300.0 million of shares of its common stock in an underwritten public offering.